ity caused by SARS-CoV-2 as a result of the associated disease COVID-19 (Corona Virus Disease-2019). There is an urgent need for the development of therapies targeting both direct viral infection and the inflammatory immune response elicited by SARS-CoV-2. While many patients with documented SARS-CoV-2 infections have mild symptomatology, patholo